Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 85

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 1
Chunk 85
---
.  The businesses in Danaher’s Diagnostics segment market their products and services under key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMOTOME and RADIOMETER.  Manufacturing facilities are located in North America, Europe, Asia and Australia.  The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.

************************************

The following discussion includes information common to all of Danaher’s segments.

Materials

The Company’s manufacturing operations employ a wide variety of raw materials, including metallic-based components, electronic components, chemistries, original equipment manufacturers (“OEM”) products, plastics and other petroleum-based products.  Prices of oil and gas also affect the Company’s costs for freight and utilities and have an indirect impact on the cost of other purchased materials.  The Company purchases raw materials from a large number of sources around the world.  No single supplier is material to the Company.  For some components that require particular specifications or regulatory or other qualifications only a single supplier or a limited number of suppliers can readily provide such components.  The Company utilizes a number of techniques to address potential disruption in and other risks relating to its supply chain, including in certain cases the use of safety stock, alternative materials and qualification of multiple supply sources.  

During 2024, there were no material effects on the business related to the availability of raw materials.  For a further discussion of risks related to the materials and components required for the Company’s operations, refer to “Item 1A. Risk Factors.”

Intellectual Property

The Company owns numerous patents, trademarks, copyrights, trade secrets and licenses to intellectual property owned by others.  Although in aggregate the Company’s intellectual property is important to its operations, the Company does not consider any single patent, trademark, copyright, trade secret or license (or any related group of any such items) to be of material importance to any segment or to the business as a whole.  From time to time the Company engages in litigation to protect its intellectual property rights.  For a discussion of risks related to the Company’s intellectual property, refer to “Item 1A. Risk Factors.”  All capitalized brands and product names throughout this document are trademarks owned by, or licensed to, Danaher.

7

Competition

Although the Company’s businesses generally operate in highly competitive markets, the Company’s competitive position cannot be determined accurately in the aggregate or by segment since